Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 4:39:93-95.
doi: 10.1016/j.jdcr.2023.07.030. eCollection 2023 Sep.

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib

Nicole Bouché  1 , Miriam A Al-Saedy  1 , Eingun J Song  2
Affiliations
Case Reports

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib

Nicole Bouché et al. JAAD Case Rep. .
No abstract available

Keywords: biologics; clinical research; drug response; general dermatology; immunodermatology; medical dermatology.

PubMed Disclaimer

Conflict of interest statement

Eingun James Song is paid consultant at BMS, AbbVie, Eli Lilly, Janssen, Novartis, UCB, Pfizer, Amgen, Dermavant, Arcutis, Incyte, SUN, Boehringer Ingelheim, Sanofi, and Regeneron. Nicole Bouché and Miriam A. Al-Saedy have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Initial presentation before the treatment.
Fig 2
Fig 2
During the treatment with mycophenolate mofetil, before starting deucravacitinib.
Fig 3
Fig 3
Eight weeks after the treatment with deucravacitinib (6 mg daily).
Fig 4
Fig 4
Four months after the treatment with deucravacitinib (6 mg daily).
See this image and copyright information in PMC

References

    1. Okon L.G., Werth V.P. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391–404. doi: 10.1016/j.berh.2013.07.008. - DOI - PMC - PubMed
    1. Lazar A.L. Subacute cutaneous lupus erythematosus: A facultative paraneoplastic dermatosis. Clin Dermatol. 2022;40(6):728–742. doi: 10.1016/j.clindermatol.2022.07.007. - DOI - PubMed
    1. Li Q., Wu H., Liao W., et al. A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus. J Autoimmun. 2018;93:1–15. doi: 10.1016/j.jaut.2018.07.007. - DOI - PubMed
    1. Hoy S.M. Deucravacitinib: first approval. Drugs. 2022;82(17):1671–1679. doi: 10.1007/s40265-022-01796-y. - DOI - PMC - PubMed
    1. Morand E., Pike M., Merrill J.T., et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A Phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242–252. doi: 10.1002/art.42391. - DOI - PMC - PubMed

Publication types

LinkOut - more resources